Nevertheless, our data suggest that the ability to improve CMT1A-like symptoms in mice with preexisting pathology is promising for the translation of this strategy to patients who may already be experiencing the effects of CMT1A. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.